Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Assertio Therapeutics Inc (ASRT)

Assertio Therapeutics Inc (ASRT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 80,384
  • Shares Outstanding, K 64,826
  • Annual Sales, $ 311,770 K
  • Annual Income, $ 36,910 K
  • 60-Month Beta 1.89
  • Price/Sales 0.25
  • Price/Cash Flow 0.47
  • Price/Book 0.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.21
  • Number of Estimates 1
  • High Estimate -0.21
  • Low Estimate -0.21
  • Prior Year 0.65
  • Growth Rate Est. (year over year) -132.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.05 +2.44%
on 10/14/19
1.49 -27.81%
on 09/25/19
-0.28 (-20.91%)
since 09/13/19
3-Month
1.05 +2.44%
on 10/14/19
3.55 -69.70%
on 07/30/19
-2.04 (-65.53%)
since 07/12/19
52-Week
1.05 +2.44%
on 10/14/19
6.07 -82.28%
on 10/19/18
-4.44 (-80.51%)
since 10/12/18

Most Recent Stories

More News
Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of Directors

Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that Dr. David Wheadon has been appointed to the Company's Board of Directors. Dr. Wheadon is a former senior executive of AstraZeneca plc.

AZN : 43.99 (+0.94%)
ASRT : 1.09 (-12.10%)
Assertio Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference

Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the Annual Cantor Fitzgerald Global Healthcare Conference in a session scheduled for 12:35...

ASRT : 1.09 (-12.10%)
Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes

Announces Results of Annual Meeting of Shareholders

MDNA.TO : 1.20 (unch)
RGEN : 78.74 (+1.65%)
ASRT : 1.09 (-12.10%)
Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes

Announces Results of Annual Meeting of Shareholders

MDNA.TO : 1.20 (unch)
RGEN : 78.74 (+1.65%)
ASRT : 1.09 (-12.10%)
ASRT vs. ZTS: Which Stock Is the Better Value Option?

ASRT vs. ZTS: Which Stock Is the Better Value Option?

ASRT : 1.09 (-12.10%)
ZTS : 126.36 (-1.64%)
Top Ranked Value Stocks to Buy for September 9th

Top Ranked Value Stocks to Buy for September 9th

MR : 3.43 (+6.19%)
DAC : 12.47 (+11.84%)
COOP : 10.70 (+0.09%)
ASRT : 1.09 (-12.10%)
Assertio Therapeutics Enters Oversold Territory

Assertio Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

ASRT : 1.09 (-12.10%)
ASRT vs. PCRX: Which Stock Is the Better Value Option?

ASRT vs. PCRX: Which Stock Is the Better Value Option?

ASRT : 1.09 (-12.10%)
PCRX : 36.92 (-2.04%)
Assertio Therapeutics Announces Exchange Offer of $200 Million of its Currently Outstanding 2.50% Convertible Notes Due 2021

Assertio Therapeutics, Inc. (NASDAQ: ASRT) ("Assertio") today announced it has entered into separate, privately negotiated exchange agreements (the "Exchange Agreements") with a limited number of holders...

ASRT : 1.09 (-12.10%)
Assertio (ASRT) Q2 Earnings Beat Estimates

Assertio (ASRT) delivered earnings and revenue surprises of 8.70% and -2.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ASRT : 1.09 (-12.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ASRT with:

Business Summary

Assertio Therapeutics, Inc. is a pharmaceutical company. It develops and markets a product for the treatment in neurology, orphan and diseases of the central nervous system. Assertio Therapeutics, Inc., formerly known as Depomed Inc., is headquartered in Lake Forest, Illinois.

See More

Key Turning Points

2nd Resistance Point 1.29
1st Resistance Point 1.26
Last Price 1.09
1st Support Level 1.21
2nd Support Level 1.19

See More

52-Week High 6.07
Fibonacci 61.8% 4.15
Fibonacci 50% 3.56
Fibonacci 38.2% 2.97
Last Price 1.09
52-Week Low 1.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar